UBS AM Portfolio holdings
UBS Asset Management (UBS AM), a division of UBS Group AG with origins tied to the bank’s founding in 1862, is headquartered in Zurich, Switzerland, and manages hundreds of billions in assets for institutional, intermediary, and wealth management clients globally. Specializing in a broad range of investment strategies—including equities, fixed income, multi-asset, alternatives, and sustainable investing—UBS AM leverages the firm’s extensive research capabilities and global network to deliver tailored solutions. Known for its focus on risk management and innovation, it offers products like ETFs, index funds, and private market investments, catering to diverse needs from pension funds to high-net-worth individuals. As part of UBS’s broader ecosystem, UBS AM combines Swiss precision with a commitment to ESG principles, solidifying its position as a leader in the asset management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$204M |
| 2 |
WBA
Walgreens Boots Alliance
WBA
|
+$163M |
| 3 |
Visa
V
|
+$141M |
| 4 |
Alibaba
BABA
|
+$137M |
| 5 |
Freeport-McMoran
FCX
|
+$130M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
K
Kellanova
K
|
+$196M |
| 2 |
Infosys
INFY
|
+$163M |
| 3 |
Monster Beverage
MNST
|
+$144M |
| 4 |
Mastercard
MA
|
+$128M |
| 5 |
Procter & Gamble
PG
|
+$119M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 14.83% |
| 2 | Technology | 14.48% |
| 3 | Financials | 14.28% |
| 4 | Consumer Discretionary | 9% |
| 5 | Industrials | 8.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1426
Bausch Health
BHC
$2.26B
| $1.26M | ﹤0.01% |
9,600
-8,200
| -46% | -$977K |
|
|
RVNC
1427
DELISTED
Revance Therapeutics, Inc.
RVNC
| $1.26M | ﹤0.01% |
65,200
| – | – |
|
1428
Equinor
EQNR
$92B
| $1.26M | ﹤0.01% |
46,325
+14,638
| +46% | +$423K |
|
1429
Designer Brands
DBI
$334M
| $1.25M | ﹤0.01% |
41,518
| – | – |
|
1430
Schwab Emerging Markets Equity ETF
SCHE
$12.8B
| $1.25M | ﹤0.01% |
49,114
+16,447
| +50% | +$442K |
|
1431
Minerals Technologies
MTX
$2.4B
| $1.25M | ﹤0.01% |
20,199
| – | – |
|
|
VTLE
1432
DELISTED
Vital Energy
VTLE
| $1.24M | ﹤0.01% |
2,765
+110
| +4% | +$56.1K |
|
1433
CDW
CDW
$17.8B
| $1.24M | ﹤0.01% |
39,900
+7,000
| +21% | +$221K |
|
1434
Wendy's
WEN
$1.46B
| $1.24M | ﹤0.01% |
150,104
| – | – |
|
|
AXE
1435
DELISTED
Anixter International Inc
AXE
| $1.24M | ﹤0.01% |
14,599
+300
| +2% | +$27.2K |
|
1436
Nice
NICE
$5.63B
| $1.23M | ﹤0.01% |
30,247
-433
| -1% | -$17.2K |
|
|
SCTY
1437
DELISTED
SolarCity Corporation
SCTY
| $1.23M | ﹤0.01% |
20,600
+300
| +1% | +$20.6K |
|
1438
Sanmina
SANM
$10.8B
| $1.23M | ﹤0.01% |
58,797
+2,200
| +4% | +$51.2K |
|
1439
Wolverine World Wide
WWW
$1.61B
| $1.22M | ﹤0.01% |
48,796
| – | – |
|
1440
Manhattan Associates
MANH
$11B
| $1.22M | ﹤0.01% |
36,500
| – | – |
|
1441
Knowles
KN
$3.39B
| $1.22M | ﹤0.01% |
45,896
-19,066
| -29% | -$582K |
|
|
AVNR
1442
DELISTED
AVANIR PHARMACEUTICALS, INC CL A
AVNR
| $1.22M | ﹤0.01% |
101,894
+2,800
| +3% | +$19.1K |
|
1443
iShares Core S&P 500 ETF
IVV
$900B
| $1.21M | ﹤0.01% |
+6,100
| New | +$1.21M |
|
|
MDRX
1444
DELISTED
Veradigm Inc. Common Stock
MDRX
| $1.21M | ﹤0.01% |
90,246
| – | – |
|
|
HTS
1445
DELISTED
HATTERAS FINANCIAL CORP
HTS
| $1.21M | ﹤0.01% |
67,285
| – | – |
|
1446
Belden
BDC
$5.04B
| $1.2M | ﹤0.01% |
18,799
| – | – |
|
|
IRF
1447
DELISTED
INTL RECTIFIER CORP
IRF
| $1.2M | ﹤0.01% |
30,497
| – | – |
|
|
BERY
1448
DELISTED
Berry Global Group, Inc.
BERY
| $1.19M | ﹤0.01% |
51,470
+7,623
| +17% | +$174K |
|
1449
Tidewater
TDW
$3.97B
| $1.19M | ﹤0.01% |
942
| – | – |
|
1450
Upbound Group
UPBD
$1.16B
| $1.19M | ﹤0.01% |
39,098
+3,600
| +10% | +$96.8K |
|
Similar funds
UBS AM's Q3 2014 Portfolio in Review
As of Q3 2014, UBS AM held 2,623 positions worth $101B, up 1.8% from $99B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
UBS AM's Q3 2014 filing shows 68 new, 1,056 increased, 515 reduced and 65 closed positions. Its largest new stake was Alibaba: 1,521,250 shares worth $135M. The largest sale was Kellanova, an estimated $196M.
By sector, the portfolio is most concentrated in Healthcare at 15% of assets, up from 14% a quarter earlier, followed by Technology and Financials.
- UBS AM's largest Q3 2014 buy was Alibaba: 1,521,250 shares worth $135M.
- UBS AM added most to Apple in Q3 2014, an estimated $204M increase.
- UBS AM's biggest Q3 2014 reduction was Kellanova, cutting an estimated $196M.
- UBS AM fully exited FOREST LABORATORIES INC in Q3 2014, selling an estimated $80.9M.
- UBS AM's ten largest holdings make up 15% of its $101B portfolio in Q3 2014.
- UBS AM opened 68 new positions and closed 65 in Q3 2014.
- UBS AM's portfolio value rose 1.8% quarter-over-quarter to $101B.
Based on UBS AM's 13F filing for Q3 2014, filed 28 Oct 2014.